COLLATERAL THERAPEUTICS INC
S-8, EX-99.4, 2000-07-07
COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Previous: COLLATERAL THERAPEUTICS INC, S-8, EX-99.3, 2000-07-07
Next: COLLATERAL THERAPEUTICS INC, S-8, EX-99.5, 2000-07-07



<PAGE>


                                                                    EXHIBIT 99.4


                                    ADDENDUM
                                       TO
                             STOCK OPTION AGREEMENT


         The following provisions are hereby incorporated into, and are hereby
made a part of, that certain Stock Option Agreement (the "Option Agreement") by
and between Collateral Therapeutics, Inc. (the "Corporation") and ___________
("Optionee") evidencing the stock option (the "Option") granted this date to
Optionee under the terms of the Corporation's 1998 Stock Incentive Plan, and
such provisions shall be effective immediately with such grant date. All
capitalized terms in this Addendum, to the extent not otherwise defined herein,
shall have the meanings assigned to them in the Option Agreement.

                        LIMITED STOCK APPRECIATION RIGHT

         1. Optionee is hereby granted a limited stock appreciation right
exercisable upon the following terms and conditions:

                  (i) Optionee shall have the unconditional right, exercisable
         at any time during the thirty (30)-day period immediately following a
         Hostile Take-Over, to surrender the Option to the Corporation, to the
         extent the Option is at the time exercisable for one or more shares of
         Common Stock. In return for the surrendered Option, Optionee shall
         receive a cash distribution from the Corporation in an amount equal to
         the excess of (A) the Take-Over Price of the shares of Common Stock for
         which the surrendered option (or surrendered portion) is at the time
         exercisable over (B) the aggregate Exercise Price payable for such
         shares.

                  (ii) To exercise this limited stock appreciation right,
         Optionee must, during the applicable thirty (30)-day exercise period,
         provide the Corporation with written notice of the option surrender in
         which there is specified the number of Option Shares as to which the
         Option is being surrendered. Such notice must be accompanied by the
         return of Optionee's copy of the Option Agreement, together with any
         written amendments to such Agreement. The cash distribution shall be
         paid to Optionee within five (5) business days following such delivery
         date. The exercise of the limited stock appreciation right in
         accordance with the terms of this Addendum is hereby approved by the
         Plan Administrator, in advance of such exercise, and no further
         approval of the Plan Administrator or the Board shall be required at
         the time of the actual option surrender and cash distribution. Upon
         receipt of such cash distribution, the Option shall be cancelled with
         respect to the Option Shares for which the Option has been surrendered,
         and Optionee shall cease to have any further right to acquire those
         Option Shares under the Option Agreement. The Option shall, however,
         remain outstanding and exercisable for the balance of the Option Shares
         (if any) in accordance with the terms of the Option Agreement, and the
         Corporation shall issue a replacement stock option agreement
         (substantially in the same form of the surrendered Option Agreement)
         for those remaining Option Shares.

                  (iii) In no event may this limited stock appreciation right be
         exercised when there is not a positive spread between the Fair Market
         Value of the Option Shares subject to the surrendered option and the
         aggregate Exercise Price payable for such shares. This limited stock
         appreciation right shall in all events terminate upon the expiration or
         sooner termination of the Option term and may not be assigned or
         transferred by Optionee, except to the extent the Option is
         transferable in accordance with the provisions of the Option Agreement.

         2. For purposes of this Addendum, the following definitions shall be in
effect:

                  (i) A HOSTILE TAKE-OVER shall be deemed to occur upon the
         acquisition, directly or indirectly, by any person or related group of
         persons (other than the Corporation or a person that directly or
         indirectly controls, is controlled by, or is under common control with,
         the Corporation) of beneficial


                                       1
<PAGE>


         ownership (within the meaning of Rule 13d-3 of the 1934 Act) of
         securities possessing more than fifty percent (50%) of the total
         combined voting power of the Corporation's outstanding securities
         pursuant to a tender or exchange offer made directly to the
         Corporation's stockholders which the Board does not recommend such
         stockholders to accept.

                  (ii) The TAKE-OVER PRICE per share shall be deemed to be equal
         to the GREATER of (A) the Fair Market Value per Option Share on the
         option surrender date or (B) the highest reported price per share of
         Common Stock paid by the tender offeror in effecting the Hostile
         Take-Over. However, if the surrendered Option is designated as an
         Incentive Option in the Grant Notice, then the Take-Over Price shall
         not exceed the clause (A) price per share.

         IN WITNESS WHEREOF, Collateral Therapeutics, Inc. has caused this
Addendum to be executed by its duly-authorized officer as of the Effective Date
specified below.

                                        COLLATERAL THERAPEUTICS, INC.



                                        By:_______________________________
                                        Title:____________________________


EFFECTIVE DATE: __________________, _____


                                       2


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission